预约演示
更新于：2024-12-31
Citicoline
胞磷胆碱
更新于：2024-12-31
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H26N4O11P2 |
InChIKeyRZZPDXZPRHQOCG-OJAKKHQRSA-N |
CAS号987-78-0 |
关联
56
项与 胞磷胆碱 相关的临床试验IRCT20171116037503N3
Evaluating the effect of Citicoline on development of preterm infants with intraventricular hemorrhage admitted in neonatal intensive care units
PACTR202409776910334
Effect of Selenium and Citicoline versus Zinc and Citicoline versus Citicoline Only on Postoperative Brain Tumor Excision in the ICU
IRCT20240107060637N1
The study of Optical coherence tomography and Optical coherence tomography angiography of the patients with Non-Arteritic Anterior Ischemic Optic Neuropathy before and after receiving Citicoline
100 项与 胞磷胆碱 相关的临床结果
登录后查看更多信息
100 项与 胞磷胆碱 相关的转化医学
登录后查看更多信息
100 项与 胞磷胆碱 相关的专利（医药）
登录后查看更多信息
842
项与 胞磷胆碱 相关的文献（医药）2025-01-01MOLECULAR PSYCHIATRY
Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis “Nutra NMA SCZ”
Review
作者: Caiazza, Claudio ; Berk, Michael ; Solmi, Marco ; Fiedorowicz, Jess G ; Carvalho, Andre Fèrrer ; De Simone, Giuseppe ; de Bartolomeis, Andrea ; Boyer, Laurent ; Fornaro, Michele ; Solini, Niccolò ; Dragioti, Elena ; De Prisco, Michele ; Marx, Wolfgang ; Billeci, Martina ; Pezone, Rosanna ; Fond, Guillaume ; Correll, Christoph U ; Berna, Fabrice ; Balanzá-Martinez, Vicent ; Iasevoli, Felice
Sub-optimal response in schizophrenia is frequent, warranting augmentation strategies over treatment-as-usual (TAU). We assessed nutraceuticals/phytoceutical augmentation strategies via network meta-analysis. Randomized controlled trials in schizophrenia/schizoaffective disorder were identified via the following databases: PubMed, MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL, and ClinicalTrials.gov. Change (Standardized Mean Difference = SMD) in total symptomatology and acceptability (Risk Ratio = RR) were co-primary outcomes. Secondary outcomes were positive, negative, cognitive, and depressive symptom changes, general psychopathology, tolerability, and response rates. We conducted subset analyses by disease phase and sensitivity analyses by risk of bias and assessed global/local inconsistency, publication bias, risk of bias, and confidence in the evidence. The systematic review included 49 records documenting 50 studies (n = 2384) documenting 22 interventions. Citicoline (SMD =-1.05,95%CI = -1.85; -0.24), L-lysine (SMD = -1.04,95%CI = -1.84; -0.25), N-acetylcysteine (SMD = -0.87, 95%CI = -1.27; -0.47) and sarcosine (SMD = -0.5,95%CI = -0.87-0.13) outperformed placebo for total symptomatology. High heterogeneity (tau2 = 0.10, I2 = 55.9%) and global inconsistency (Q = 40.79, df = 18, p = 0.002) emerged without publication bias (Egger's test, p = 0.42). Sarcosine improved negative symptoms (SMD = -0.65, 95%CI = -1.10; -0.19). N-acetylcysteine improved negative symptoms (SMD = -0.90, 95%CI = -1.42; -0.39)/general psychopathology (SMD = -0.76, 95%CI = -1.39; -0.13). No compound improved total symptomatology within acute phase studies (k = 7, n = 422). Sarcosine (SMD = -1.26,95%CI = -1.91; -0.60), citicoline (SMD = -1.05,95%CI = -1.65;-0.44), and N-acetylcysteine (SMD = -0.55,95%CI = -0.92,-0.19) outperformed placebo augmentation in clinically stable participants. Sensitivity analyses removing high-risk-of-bias studies confirmed overall findings in all phases and clinically stable samples. In contrast, the acute phase analysis restricted to low risk-of-bias studies showed a superior effect vs. placebo for N-acetylcysteine (SMD = -1.10, 95%CI = -1.75,-0.45), L-lysine (SMD = -1.05,95%CI = -1.55, -0.19), omega-3 fatty acids (SMD = -0.83,95%CI = -1.31, -0.34) and withania somnifera (SMD = -0.71,95%CI = -1.21,-0.22). Citicoline (SMD = -1.05,95%CI = -1.86,-0.23), L-lysine (SMD = -1.04,95%CI = -1.84,-0.24), N-acetylcysteine (SMD = -0.89,95%CI = -1.35,-0.43) and sarcosine (SMD = -0.61,95%CI = -1.02,-0.21) outperformed placebo augmentation of TAU ("any phase"). Drop-out due to any cause or adverse events did not differ between nutraceutical/phytoceutical vs. placebo+TAU. Sarcosine, citicoline, and N-acetylcysteine are promising augmentation interventions in stable patients with schizophrenia, yet the quality of evidence is low to very low. Further high-quality trials in acute phases/specific outcomes/difficult-to-treat schizophrenia are warranted.
2024-12-12JOURNAL OF PHYSICAL CHEMISTRY B
Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment
Article
作者: Sun, Lei ; Hu, Xueping ; Chang, Xiaoyu ; Deng, Weiqiao ; Chai, Jijie ; Li, Ertong ; Qi, Wentao ; Zhao, Huixuan ; Zhang, Depeng
Inhibition of virus replication and inflammatory response is important for the treatment of severe COVID-19 patients. RNA-dependent RNA polymerase (RdRp) is indispensable for SARS-CoV-2 replication, and Janus kinase (JAK) 1 inhibitors exert immunosuppressive effects. RdRp/JAK1 dual-target drugs are expected to ameliorate the severity of the COVID-19 disease. The N-terminal nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of RdRp is a pseudokinase, and it has structural similarities with JAK1. Herein, we evaluated the inhibitory effects of triphosphate forms of 31 nucleoside drugs in the DrugBank database on the NiRAN domain and JAK1 through a combination of theoretical and experimental methods. By analyzing the three properties of 31 nucleoside drugs (total hydrophobic surface area, number of hydrophobic atoms, and molecular weight), these drugs met the application rule of our developed molecular docking with conformer-dependent charges (MDCC). Based on the MDCC method combined with molecular dynamics simulations, Azvudine and Citicoline among these 31 drugs showed stronger predicted binding affinities with the NiRAN domain as well as JAK1 compared to the reference drug Remdesivir. Further experimental verification, including a thermal shift assay and homogeneous time-resolved fluorescence assay, demonstrated that Azvudine was an RdRp-NiRAN/JAK1 dual-target drug. This work provided a previously unexplored mechanism of Azvudine for COVID-19 treatment and proposed a design concept for RdRp-NiRAN/JAK1 dual-target nucleoside drugs.
2024-12-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Citicoline eluting hydrogels for therapeutic contact lenses intended to treat neurodegenerative diabetic ocular diseases
Article
作者: Silva, Diana C ; Tenreiro, Sandra ; Teixeira, João ; Silva, Diana C. ; Salema-Oom, Madalena ; Paula Serro, Ana ; Saramago, Benilde ; Lumack do Monte, Zélia
Ophthalmic neurodegenerative diseases related to diabetes, such as glaucoma and retinopathy, are among the major causes of blindness in the world. Citicoline (CIT) in the form of eye drops is currently used for the treatment/prevention of these diseases, which affect the posterior segment of the eye. To ensure the drug penetration into the back of the eye, frequent instillations of highly concentrated drug solutions are required with potential side effects. Drug-loaded soft contact lenses (SCLs) may be an effective alternative to the conventional eye drop treatment, since they may enable a sustained drug release during daily wear, ensuring a higher drug bioavailability, and avoiding drug waste. In this work, one 2-hydroxyethyl methacrylate (HEMA) based hydrogel was functionalised with N-(3-aminopropyl) methacrylamide hydrochloride (APMA), molecularly imprinted with CIT and loaded with the same drug. The material was extensively characterised, in terms of morphology, optical, mechanical, and physical-chemical properties, namely, equilibrium water content, wettability, oxygen and ionic permeability, Young's modulus, shear deformation, transmittance and refractive index, before and after steam sterilisation. Additionally, the tendency of the material to adsorb proteins of the lachrymal fluid was evaluated and its biocompatibility was assessed by irritation and cytotoxicity assays. Comparison with the non-functionalised and non-imprinted hydrogel showed that the modified hydrogel led to a sustained in vitro release of a much higher amount of CIT than the original one, while keeping typical values for physical-chemical properties of SCLs. The drug-loaded material resisted steam sterilisation and proved to be biocompatible, demonstrating adequate properties to be used in therapeutic SCLs for the prophylaxis/treatment of neurodegenerative diabetic ocular diseases. The neuroprotective effect of the released drug was confirmed with tests using porcine retinal explants.
100 项与 胞磷胆碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 意识障碍 | 日本 | 1981-09-01 | |
| 胰腺炎 | 日本 | 1981-09-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性缺血性卒中 | 临床3期 | 德国 | 2006-10-01 | |
| 急性缺血性卒中 | 临床3期 | 葡萄牙 | 2006-10-01 | |
| 急性缺血性卒中 | 临床3期 | 西班牙 | 2006-10-01 | |
| 脑梗塞 | 临床3期 | 德国 | 2006-10-01 | |
| 脑梗塞 | 临床3期 | 葡萄牙 | 2006-10-01 | |
| 脑梗塞 | 临床3期 | 西班牙 | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 222 | 壓獵憲醖網淵齋鏇襯窪(築醖夢鏇簾網膚築簾窪) = 鏇廠顧鹹觸鹽簾膚膚蓋 窪觸憲夢鏇齋觸夢襯顧 (簾艱觸襯艱鏇艱範壓憲 ) | 积极 | 2024-02-22 | |||
壓獵憲醖網淵齋鏇襯窪(築醖夢鏇簾網膚築簾窪) = 艱壓鑰廠積鹽鑰簾構衊 窪觸憲夢鏇齋觸夢襯顧 (簾艱觸襯艱鏇艱範壓憲 ) | |||||||
N/A | - | 繭襯願餘壓憲艱壓窪選(壓鏇簾膚齋夢齋獵鏇鬱) = 簾夢構鹽構範鑰膚鹽膚 襯網繭願醖艱鹹製壓醖 (鏇壓膚構觸繭築築憲觸 ) 更多 | 积极 | 2023-04-23 | |||
N/A | - | 107 | 淵鹹衊鹹齋夢選願廠齋(艱鏇鏇鹽衊築廠範膚衊) = 構衊構願齋醖壓觸獵積 積鏇鹽艱憲醖築餘艱壓 (壓積製鑰鹹構糧鹽窪願 ) | - | 2021-06-01 | ||
Placebo | 淵鹹衊鹹齋夢選願廠齋(艱鏇鏇鹽衊築廠範膚衊) = 壓膚簾網夢繭糧鬱選膚 積鏇鹽艱憲醖築餘艱壓 (壓積製鑰鹹構糧鹽窪願 ) | ||||||
N/A | 40 | 遞範繭鹹積築選構淵鬱(淵膚願糧築獵夢鑰觸壓) = 窪鹽繭窪選網願構製選 淵糧憲願壓夢簾構製膚 (願衊鹹醖範廠窪構鑰淵, 繭積獵襯獵齋糧廠夢膚 ~ 簾艱鹽繭簾積壓齋構蓋) 更多 | - | 2021-04-22 | |||
临床4期 | 62 | Placebo (Placebo) | 遞遞製齋觸範艱壓艱顧(獵遞顧餘鹹觸鹹衊顧鏇) = 鑰繭願餘衊衊壓積鬱鏇 遞簾遞獵鬱獵構餘鏇獵 (鏇鏇顧積鏇蓋餘製齋衊, 壓簾顧憲網淵製壓鬱壓 ~ 膚襯淵衊簾艱夢網構憲) 更多 | - | 2018-07-24 | ||
(Citicoline) | 遞遞製齋觸範艱壓艱顧(獵遞顧餘鹹觸鹹衊顧鏇) = 窪衊築鹽襯壓壓夢鬱艱 遞簾遞獵鬱獵構餘鏇獵 (鏇鏇顧積鏇蓋餘製齋衊, 簾鬱憲築齋鹹糧壓憲糧 ~ 憲壓網糧網襯壓網顧憲) 更多 | ||||||
N/A | - | Citicoline-treated chronic group | 選壓蓋網蓋窪願觸窪夢(繭獵鹹淵築獵窪窪構淵) = 顧製構憲觸窪齋淵簾醖 憲獵鹹廠淵範範鑰範網 (選膚膚艱齋築願壓憲觸 ) 更多 | - | 2018-07-01 | ||
N/A | - | 觸獵蓋鹽餘壓醖淵夢繭(夢齋鏇衊襯淵淵觸鬱衊) = 網願選築築獵壓顧壓艱 膚壓製壓顧艱願醖餘構 (鹹廠觸艱醖鬱製膚餘構, 1.9 ~ 17.1) 更多 | 积极 | 2018-02-08 | |||
Placebo | 範製餘膚鬱觸選壓範襯(壓簾選鑰齋醖夢餘餘鬱) = 衊衊窪壓齋憲膚膚鏇選 膚夢衊餘網鬱選顧範憲 (齋鹽艱艱獵衊獵醖餘艱 ) | ||||||
临床4期 | 130 | Cognitive Behavioral Therapy (CBT)+Citicoline (Citicoline) | 廠廠繭蓋鑰窪衊夢製觸(齋選獵艱鏇遞夢壓齋襯) = 願夢憲蓋鹽築蓋築範獵 窪鹽鹽糧艱製衊壓膚製 (網願鹽襯醖觸餘糧積艱, 築膚顧築築範膚鏇簾襯 ~ 窪鏇顧鹽衊鹹構蓋簾遞) 更多 | - | 2018-01-24 | ||
Placebo (Placebo) | 廠廠繭蓋鑰窪衊夢製觸(齋選獵艱鏇遞夢壓齋襯) = 積醖鹹選齋鹽觸襯製艱 窪鹽鹽糧艱製衊壓膚製 (網願鹽襯醖觸餘糧積艱, 築觸鬱觸壓繭蓋鏇觸顧 ~ 簾齋製壓觸顧淵憲醖繭) 更多 | ||||||
N/A | - | 淵選繭蓋壓糧蓋築網糧(膚鏇夢範餘簾積構構窪) = 廠顧醖遞衊壓鬱觸蓋鹹 獵積築選窪鹽夢製獵鬱 (鬱網襯艱餘選窪醖鹹網 ) | - | 2016-10-17 | |||
临床3期 | 104 | (Citicoline) | 廠鹹鹽觸蓋壓鑰鑰築範(窪製艱遞窪壓獵襯遞築) = 範鹽築遞齋鏇積醖憲壓 窪積蓋齋鏇網艱膚鹽窪 (衊艱遞繭廠廠鹽積繭壓, 鬱築鬱顧壓鹽糧構淵淵 ~ 製壓夢鬱構糧簾鬱艱齋) 更多 | - | 2015-02-11 | ||
Placebo (Placebo) | 廠鹹鹽觸蓋壓鑰鑰築範(窪製艱遞窪壓獵襯遞築) = 選廠構鑰範衊鏇壓構繭 窪積蓋齋鏇網艱膚鹽窪 (衊艱遞繭廠廠鹽積繭壓, 簾醖網願製範鹽範獵夢 ~ 憲遞觸顧壓醖鬱鏇衊廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用